G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker

详细信息	查看全文 | 推荐本文 |

• 作者：Xiaoyi Zheng^c ; Frank Chang^c ; Xinmin Zhang^b ; Vicki L. Rothman^a ; George P. Tuszynski^a ; ^{gpt@temple.edu}
• 关键词：DCIS ; ductal carcinoma in situ ; GASP-1 ; G-protein coupled receptor-associated sorting protein 1 ; GASP-1 ; 2-D high performance liquid electrophoresis ; 2-D HPLE ; PBS ; phosphate buffered saline ; PAGE ; polyacrylamide gel electrophoresis ; PVDF ; polyvinylidene
• 刊名：Experimental and Molecular Pathology
• 出版年：2012
• 期刊代码：291_00144800
• 类别：med
• 出版时间：August, 2012
• 卷：93
• 期：1
• 页码：111-115
• 文件大小：943 K

摘要

Using an innovative 鈥?-D high performance liquid electrophoresis鈥?(2-D HPLE) technology we identified that a specific fragment of G-protein coupled receptor-associated sorting protein 1 (GASP-1) was present in the sera of breast cancer patients and was over-expressed in early and late stage breast tumors (Tuszynski, G.P. et al., 2011). In this study we further investigated the significance of GASP-1 as a tumor marker by investigating the expression GASP-1 in different kinds of tumors as well as in the sera of patients with various cancers. Over expression of GASP-1 was detected in brain, pancreatic, and breast cancers as compared to their respective normal tissues as assessed by immunohistochemical staining of tissue arrays using a 鈥減eptide specific鈥?GASP-1 antibody. We found that across these cancers, GASP-1 was expressed approximately 10 fold more in the cancer as compared to normal tissue. The increase in GASP-1 expression was also seen in hyperplastic and inflammatory lesions of breast and pancreatic cancers as compared to normal tissue. GASP-1 was primarily expressed in the tumor epithelium of the epithelial-derived cancers and in the transformed glial cells of the brain tumors. Using a sensitive 鈥渃ompetitive ELISA鈥?for GASP-1, we found that sera from patients with brain, liver, breast and lung cancers expressed 4-7 fold more GASP-1 peptide than sera from normal healthy individuals. These studies identify GASP-1 as a potential new serum and tumor biomarker for several cancers and suggest that GASP-1 may be a novel target for development of cancer therapeutics.